ArticleFrontiers in oncology2025
Validated nomograms for non-metastatic colorectal cancer prognosis prediction: a population-based study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- HighTranslational cancer research · 2026Article
- Posterior minimal extrathyroidal extension as an independent risk factor for lateral lymph node metastasis in papillary thyroid carcinoma: a retrospective study based on a nomogram prediction model.Frontiers in endocrinology · 2026Article
- Albumin and neutrophil combined prognostic grade for predicting overall survival in colorectal cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The TNM staging system has limitations in predicting prognosis for colorectal cancer (CRC). This study aimed to develop and validate a nomogram incorporating the albumin-derived neutrophil-to-lymphocyte ratio (Alb-dNLR) score, a novel nutritional and inflammatory biomarker, to provide a more accurate and personalized prognostic prediction for patients with non-metastatic CRC. Methods: This retrospective study included a development cohort of 457 non-metastatic CRC patients who underwent radical colectomy, and an external validation cohort of 207 patients. Optimal cut-off values for continuous variables were determined by ROC curve analysis. Multivariable Cox and LASSO regression models were used to identify independent prognostic factors for cancer-specific survival (CSS) and to construct two nomograms. The performance of the nomograms was assessed by C-indexes, calibration plots, and decision curve analysis (DCA). Results: Multivariable analysis confirmed that a high Alb-dNLR score was an independent predictor for worse cancer-specific survival (CSS) (HR = 5.536, P < 0.001) and overall survival (OS) (HR = 4.690, P < 0.001). Both nomograms, developed from Cox and LASSO models, showed superior discrimination compared to the TNM staging system alone (C-index in development cohort: (0.785, 0.767 vs. 0.680). Calibration plots and DCA confirmed the nomograms' accuracy and clinical utility in both cohorts. Conclusions: The Alb-dNLR score is a simple and effective independent prognostic biomarker for non-metastatic CRC. The nomograms incorporating Alb-dNLR score provide a more accurate and practical tool than the TNM system for predicting patient survival, thereby facilitating personalized clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.